August 4, 2025

Figure S8 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

View Full Paper

Ask AI

Bookmark

Main finding reveals that multi-selective inhibitor combination therapy can control tumors long-term.
Data suggest this approach fosters senescence-associated tumor-immune equilibrium in pancreatic ductal adenocarcinoma.
Flow cytometry was used to analyze immune cell responses in the tumor environment.
This work provides insights into potential new treatments for pancreatic cancer, aiming for improved patient outcomes.

Implication

Combination therapy improves tumor control in pancreatic ductal adenocarcinoma, suggesting a role for immune equilibrium.

Gating strategy for flow cytometry analysis in Fig 3A-B and Supplementary Fig S4A-N, S4Q-S.

No takes yet. Share an insight, caveat, or question.

Broderick et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Combination therapy improves tumor control in pancreatic ductal adenocarcinoma, suggesting a role for immune equilibrium.

Gating strategy for flow cytometry analysis in Fig 3A-B and Supplementary Fig S4A-N, S4Q-S.